科美诊断收盘下跌1.83%，滚动市盈率33.42倍，总市值34.50亿元

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kemei Diagnostics, indicating a decline in revenue and profit while showcasing its innovation capabilities through patent acquisitions [1][2]. Group 2 - Kemei Diagnostics closed at 8.6 yuan, down 1.83%, with a rolling PE ratio of 33.42 times and a total market value of 3.45 billion yuan [1]. - The average PE ratio for the medical device industry is 54.24 times, with a median of 37.92 times, placing Kemei Diagnostics at the 69th position in the industry ranking [1]. - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous period, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1]. - The main business of Kemei Diagnostics includes the research, development, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments, with key products being the LiCA and CC series [1]. - During the reporting period, the company obtained 64 new domestic and international authorized patents, including 33 domestic invention patents, 20 domestic utility model patents, and 11 design patents, reflecting its growing innovation capability and technical reserves [1]. - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported revenue of 81.30 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1].